Cangrelor dose adjustment using platelet testing for patients awaiting coronary procedures
Official title: The Bridging Antiplatelet Therapy With Cangrelor 2 (BRIDGE 2) Study: A Pilot Prospective Cohort, Pharmacodynamic Study of Tailored Cangrelor Bridging Dosing Regimens
Run by University of Florida · NCT07225842 · Data updated 2026-11-12
This trial tests whether adjusting the cangrelor infusion based on platelet-function testing keeps platelet reactivity in the target range for adults with coronary artery disease awaiting coronary procedures.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 50 (estimated) |
| Sponsor | University of Florida Academic / other |
| Locations | 1 site (Jacksonville, Florida) |
| Status | Recruiting |
| Started | February 18, 2026 |
| Main results expected | September 2027 |
| Study ends | November 2027 |
| Registry record updated | November 6, 2026 |
| Trial ID | NCT07225842 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18) with coronary artery disease who have been on standard-dose cangrelor (0.75 mcg/kg/min) for at least two hours while awaiting coronary intervention or CABG and who can provide informed consent are ideal candidates.
✕Probably not a fit
Patients needing urgent surgery, pregnant or lactating women, those recently exposed to oral P2Y12 inhibitors or anticoagulants, or with known contraindications to cangrelor are excluded and unlikely to benefit from this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a prospective, single-arm, open-label pharmacodynamic study at UF Health Jacksonville enrolling inpatients with established coronary artery disease who are being bridged with cangrelor. After at least two hours on the standard 0.75 mcg/kg/min infusion, participants receive a baseline PRU measurement with the VerifyNow system and the infusion is titrated: reduced to 0.50 mcg/kg/min if PRU ≤208 or increased to 1.0 mcg/kg/min if PRU >208, aiming for a PRU range of 85–208. Study procedures are research-only and performed without delaying the planned coronary intervention or CABG; if the procedure is moved earlier the study procedures stop. Enrollment and screening are performed by the cardiology research staff on the inpatient units.
Why it matters
Potential benefit: If successful, this approach could keep platelet reactivity within the therapeutic window during pre-procedure bridging and may lower the risk of clotting or bleeding around coronary procedures.
How similar studies have gone: Previous trials have shown cangrelor can maintain platelet inhibition during bridging, but platelet-function-test–guided dose titration is a newer strategy with limited prior evidence.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Any patient receiving bridging with standard-dose cangrelor infusion rate of 0.75 mcg/Kg/min for at least two hours as part of their standard of care. 2. Age ≥18 years 3. Provide written informed consent. Exclusion Criteria: 1. Need for urgent surgery 2. Confirmed or suspected pregnancy (in woman of child-bearing potential) or lactating females 3. Exposure to any oral P2Y12 inhibitor, oral anticoagulant or glycoprotein IIb/IIIa inhibitor within 48 hours. 4. Known allergy, and hypersensitivity, or contraindication to cangrelor, mannitol, sorbitol, or microcrystalline cellulose
Where it's running
-
University of Florida Jacksonville
Jacksonville, Florida, United States Recruiting
Study contacts
- Principal investigator: Luis Ortegra-Paz, MD, PhD — University of Florida College of Medicine - Jacksonville
- Study coordinator: Luis Ortega-Paz, MD, PhD
- Email: Luis.Ortega@jax.ufl.edu
- Phone: 904-244 2060
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Red grape juice and metabolism in men with coronary disease
Researchers will test whether daily red grape juice changes the blood metabolite profile in men with chronic coronary artery disease.
-
Edoxaban vs. Apixaban in AF with CAD: Net Benefit
This trial tests whether edoxaban-based therapy provides a similar or better overall benefit than apixaban-based therapy for stroke prevention and major bleeding in adults with atrial fibrillation and coronary artery disease.
-
Revascularization of Calcified Coronary Arteries
This study tests whether measuring blood flow and pressure before and after ballooning or stenting of calcified coronary arteries can help predict how well the procedure will work for adults with heart disease.
-
OPN Balloon Use for Recanalization of Calcified Coronary Lesions
This registry tests how the SIS-OPN balloon is used in real-world patients with calcified coronary disease who have undergone PCI in North America.
-
Pulse IVL to open calcified coronary vessels in CAD
A small, early feasibility study tests the Pulse Intravascular Lithotripsy system in adults with coronary artery disease to see if it can safely open calcified arteries and improve vessel compliance.
-
Crystalline sirolimus-coated balloon for treating coronary artery disease
This tests whether a crystalline sirolimus-coated balloon is safe and effective for adults having percutaneous coronary intervention for coronary artery blockages or in-stent restenosis.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.